| Literature DB >> 35754694 |
Ana Carolina Proença1, Ângelo Luís1,2, Ana Paula Duarte1,2.
Abstract
Over the past few decades, interest in medicinal plants and phytochemicals for the treatment of skin disorders, including acne vulgaris, has progressively increased. Acne vulgaris is a chronic inflammatory disease of the pilosebaceous unit, which mainly occurs in adolescents and young adults. The treatment focuses on the four main factors involved in its pathogenesis: increased sebum production, hyperkeratinization, overgrowth of Cutibacterium acnes, and inflammation. The treatment includes topical retinoids, benzoyl peroxide, antibiotics, and oral isotretinoin. In this regard, the use of herbal medicine as a complementary and alternative medicine is a promising strategy. The main objective of this study was to systematically evaluate the efficacy and safety of medicinal plants and phytochemicals in the treatment of acne vulgaris. Three scientific databases (PubMed, Web of Science, and Scopus) were searched from inception to January 2021. Clinical trials comparing herbal therapies with placebo or other medicines for the treatment of acne vulgaris were included and analyzed. Outcome measures of interest comprised acne lesions (inflammatory and noninflammatory), sebum production, acne severity, and quality of life. The risk of bias in the included randomized controlled trials (RCTs) was assessed using the Cochrane risk-of-bias tool. A total of 34 clinical trials involving 1753 participants met the inclusion criteria for this systematic review. Most trials showed that herbal medicine significantly reduces inflammatory and noninflammatory acne lesions and has a relevant effect on acne severity. Some medicinal plants revealed equal or higher efficacy to standard treatments. No significant difference between groups in sebum production and quality of life was observed and no severe adverse events were reported. This systematic review provides evidence that medicinal plants and phytochemicals are promising treatments for mild to moderate acne vulgaris. However, more quality of evidence and standardized methodologies are needed to support their effectiveness and safety claims.Entities:
Year: 2022 PMID: 35754694 PMCID: PMC9217581 DOI: 10.1155/2022/2011945
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.650
Search string used for this systematic review.
|
|
| (1) Plant (1082807) |
| (2) Plant extract (188557) |
| (3) Tea (30664) |
| (4) Herbal products (7154) |
| (5) Natural products (637692) |
| (6) 1 OR 2 OR 3 OR 4 OR 5 (1547065) |
| (7) Phytotherapy (39254) |
| (8) Treatment (10562707) |
| (9) Remedy (10139) |
| (10) Natural therapy (155217) |
| (11) Herbal medicine (41337) |
| (12) 7 OR 8 OR 9 OR 10 OR 11 (10578745) |
| (13) Acne vulgaris (12303) |
| (14) Propionibacterium acnes (4976) |
| (15) 13 OR 14 (16271) |
| (16) 6 AND 12 AND 15 (732) |
| (17) 16 AND Humans AND English (362) |
|
|
|
|
| (1) Plant (4958255) |
| (2) Plant extract (463391) |
| (3) Tea (125509) |
| (4) Herbal products (43344) |
| (5) Natural products (350473) |
| (6) 1 OR 2 OR 3 OR 4 OR 5 (5283779) |
| (7) Phytotherapy (39811) |
| (8) Treatment (9089471) |
| (9) Remedy (64916) |
| (10) Natural therapy (206773) |
| (11) Herbal medicine (69546) |
| (12) 7 OR 8 OR 9 OR 10 OR 11 (9313410) |
| (13) Acne vulgaris (17168) |
| (14) |
| (15) 13 OR 14 (23700) |
| (16) 6 AND 12 AND 15 (569) |
| (17) 16 AND English (547) |
|
|
|
|
| (1) Plant (2340371) |
| (2) Plant extract (271770) |
| (3) Tea (64489) |
| (4) Herbal products (16588) |
| (5) Natural products (191436) |
| (6) 1 OR 2 OR 3 OR 4 OR 5 (2547351) |
| (7) Phytotherapy (40878) |
| (8) Treatment (7537055) |
| (9) Remedy (60029) |
| (10) Natural therapy (73955) |
| (11) Herbal medicine (53492) |
| (12) 7 OR 8 OR 9 OR 10 OR 11 (7665338) |
| (13) Acne vulgaris (14914) |
| (14) |
| (15) 13 OR 14 (21527) |
| (16) 6 AND 12 AND 15 (362) |
| (17) 16 AND English (338) |
Figure 1Flow diagram of the database search, trial selection, and articles included in this systematic review.
Main characteristics of the included studies in this systematic review.
| Author, year | Study design, duration | Participants | Intervention | Control | Outcomes | Adverse effects | |
|---|---|---|---|---|---|---|---|
|
| Acne classification (severity degree; classification system) | Herbal medicine; pharmaceutical form(s); dose/frequency; route(s) of administration | |||||
|
| |||||||
| Bassett et al., 1990 [ | RCT, 3 months | 61/63 | Mild to moderate; leeds system | Tea tree oil 5%; gel; cutaneous | Benzoyl peroxide 5% | Number of inflammatory and noninflammatory lesions | Intervention group: 44% of the participants reported dryness, itching, burning, and redness of the skin. |
| Capitanio et al., 2012 [ | RCT, 8 weeks | 30/30 | Mild; leeds system | A complex of zinc and an oligosaccharide derived from the seaweed | Placebo | Number of inflammatory and noninflammatory lesions; sebum production | Absence of irritation and skin peeling. |
| Enshaieh et al., 2007 [ | RCT, 45 days | 30/30 | Mild to moderate; injury count | Tea tree oil 5%; gel; twice a day; cutaneous | Placebo | Number of total lesions; number of inflammatory and noninflammatory lesions; acne severity (ASI) | Intervention group: itching ( |
| Forest and Rafikhah, 2014 [ | RCT, 30 days | 18/16 | Mild to moderate; leeds system |
| Placebo | Number of total lesions; number of inflammatory and noninflammatory lesions | Without adverse effects |
| Fouladi, 2012 [ | RCT, 4 weeks | 25/25 | Moderate to severe; injury count |
| Placebo | Number of total lesions; number of inflammatory and noninflammatory lesions; acne severity (Michaelson's acne severity score) | Without adverse effects |
| Hajheydari et al., 2014 [ | RCT, 8 weeks | 30/30 | Mild to moderate; GAGS |
| Placebo + tretinoin | Number of total lesions; number of inflammatory and noninflammatory lesions; acne severity (ASI) | The intervention group reported fewer adverse effects than the control group |
| Hou et al., 2018 [ | Uncontrolled trial, 4 weeks | 20 | Mild to moderate; NR |
| — | Number of inflammatory and noninflammatory lesions; sebum production | NR |
| Khan and Akhtar, 2014 [ | RCT, 12 weeks | (Female 1) 25/25 | Moderate; leeds system | (F1) | Placebo | Sebum production; global clinical evaluation | NR |
| Kwon et al., 2014 [ | RCT, 8 weeks | 34/34 | Mild to moderate; modified leeds system |
| Tea tree oil | Number of inflammatory and noninflammatory lesions; sebum production; acne severity (modified leeds system) | Intervention group: mild erythema ( |
| Lee et al., 2011 [ | RCT, 12 weeks | 50/47 | Mild to moderate; KAGS |
| Adapalene 0.1% | Number of total lesions; number of inflammatory and noninflammatory lesions; acne severity (KAGS); global clinical evaluation; participants evaluation (TR) | The intervention group reported fewer adverse effects than the control group. However, by the end of the study, the difference between the two groups became negligible. |
| Lu and Hsu, 2016 [ | RCT, 4 weeks | 40/40 | Moderate to severe; IGA |
| Placebo | Number of total lesions; number of inflammatory and noninflammatory lesions; life quality (CADI) | Intervention group: constipation ( |
| Lueangarun et al., 2019 [ | RCT, 12 weeks | 28/28 | Moderate to severe; GAGS |
| Clindamycin 1% | Number of inflammatory and noninflammatory lesions; porphyrins production; clinical global evaluation; participants evaluation (TS) | Similar adverse effects in both groups. After 4-weeks of treatment, no participant had adverse effects on both sides of the face. |
| Malhi et al., 2017 [ | Uncontrolled trial, 12 weeks | 18 | Moderate to severe; injury count and IGA | Tea tree oil; gel; twice a day; cutaneous | — | Number of total lesions; acne severity; participants evaluation (TR) | Well tolerated treatment. Moderate desquamation ( |
| Miglani and Manchanda, 2014 [ | Uncontrolled trial, 6 months | 34 | NR; GAGS |
| — | Number of total lesions; number of inflammatory and noninflammatory lesions; acne severity (GAGS); life quality (Acne-QoL) | NR |
| Orafidiya et al., 2002 [ | RCT, 4 weeks | 112/ | NR; injury count |
| (1) Benzoyl peroxide 10% | Time necessary to reduce 50% of the total number of lesions (days) | Adverse effects are minimal and tolerable |
| Pan-In et al., 2015 [ | RCT, 4 weeks | 10/10 | NR; injury count |
| Placebo | Number of inflammatory lesions; acne severity (ASI) | NR |
| Pécastaings et al., 2018 [ | Controlled trial, 56 days | 60 | Mild to moderate; |
| Healthy volunteers, free of facial or dorsal acne and of any facial dermatosis | Acne severity; porphyrins production | Without adverse effects |
| Shafiq et al., 2014 [ | RCT 45-days | 25/25 | NR; injury count |
| Benzoyl peroxide | Acne severity (Cook's Acne Grading Scale); global clinical evaluation | Intervention group: without adverse effects. |
| Sharquie et al., 2006 [ | RCT, 2 months | 30/30 | Mild to moderate; |
| Placebo | Number of inflammatory lesions; participants evaluation (TS) | Without adverse effects |
| da Silva et al., 2012 [ | Controlled clinical trials, 21 days | 10/10 | Mild; NR |
| Placebo | Area occupied by the inflammatory lesions (mm2) | Without adverse effects |
| Sutono, 2013 [ | RCT, 3 weeks | 45/41 | Mild to moderate; Lehman criteria |
| Placebo | Number of total lesions; number of inflammatory and noninflammatory lesions | Without adverse effects |
| Thappa and Dogra, 1994 [ | RCT, 3 months | 10/10 | Severe (nodulocystic); injury count |
| Tetracycline oral (500 mg) | Number of inflammatory and noninflammatory lesions | Without adverse effects |
|
| |||||||
|
| |||||||
| Beltrami et al., 2001 [ | Controlled clinical trials, 90 days | 15/15 | Mild to severe; NR |
| Topical treatment + placebo (oral) | Sebum production | Intervention group: burning (resolved with continued treatment). |
| Lone et al., 2012 [ | Uncontrolled trial, 45 days | 25 | NR; Cook's system of acne grading | Unani formulation: Irsa ( | — | Acne severity (Cook's Acne Grading Scale) | Without adverse effects |
| Kim et al., 2019 [ | RCT, 8 weeks | 28/28 | NR; injury count | Cheongsangbangpoong-tang formulation: | Placebo | Number of inflammatory and noninflammatory lesions acne severity (KAGS; IGA) | Intervention group: Digestion discomfort ( |
| Lalla et al., 2001 [ | RCT, 4 weeks | (G1) 23 (G2) 23 | Mild to severe; | Ayurvedic formulation (soft extracts of | (G3) Placebo (topical preparation) | Participants evaluation (TR) | Mild itching ( |
|
| |||||||
| Lubtikulthum et al., 2019 [ | RCT, 12 weeks | 39/38 | Mild to moderate; modified leeds system |
| Benzoyl peroxide 2.5% | Number of total lesions; number of inflammatory and noninflammatory lesions; life quality (DLQI); porphyrins production; participants evaluation (TS) | Most common adverse effect: Skin irritation. The intervention group reported fewer adverse effects (skin desquamation and erythema) than the control group. |
| Mazzarello et al., 2018 [ | RCT, 30 days | (PTA) 20 | Mild to moderate; injury count | Propolis 20%, tea tree oil 3%, and | (1) Erythromycin 3% | Number of total lesions; number of inflammatory and noninflammatory lesions; acne severity (ASI); sebum production | NR |
| Orafidiya et al., 2004 [ | RCT, 4 weeks | 48/ | NR; injury count |
| (1) Placebo | Time necessary to reduce 50% the number of inflammatory lesions (days) | Intervention group: mild and tolerable adverse effects—96% of participants reported feeling a slight burning sensation on the skin. |
| Paranjpe and Kulkarni, 1995 [ | RCT, 6 weeks | 67/15 | Moderate; injury count | 4 ayurvedic formulations; pills; 500 mg/3 times per day; oral | Placebo | Number of inflammatory and noninflammatory lesions; participants evaluation (TR) | NR |
| Parveen et al., 2009 [ | RCT, 2 months | 20/10 | NR; IGA | Unani formulation; cream; twice a day; cutaneous | Placebo | Acne severity (IGA) | NR |
|
| |||||||
|
| |||||||
| Fabbrocini et al., 2011 [ | Controlled clinical trials, 60 days | 20/20 | NR; GAGS | Resveratrol (0.01%, w/v); gel; once a day; cutaneous | Placebo | Acne severity (GAGS) | Without adverse effects |
| Jung et al., 2012 [ | Uncontrolled trial, 8 weeks | 30 | Mild to moderate; injury count (inflammatory and noninflammatory lesions) | Polyphenon-60: catechin from green tea and is the representative green tea extract compound (20 mg/mL); lotion; twice a day; cutaneous | — | Number of inflammatory and noninflammatory lesions | NR |
| Yoon et al., 2013 [ | RCT, 8 weeks | (Epigallocatechin-3-gallate 1%) 17/17 | NR; modified Leeds system | Epigallocatechin-3-gallate 1% and 5%; solution; twice a day; cutaneous | Placebo | Number of inflammatory and noninflammatory lesions; acne severity (modified leeds system) | Intervention group (5%): erythema and skin irritation ( |
ASI: Acne Severity Index; CADI: Cardiff Acne Disability Index; DLQI: Dermatology Life Quality Index; GAGS: Global Acne Grading System; GEA: Global Acne Severity Scale; IGA: Investigator's Global Assessment; KAGS: Korean Acne Grading System; NR: not eported; TR: treatment response; TS: treatment satisfaction.
Figure 2Results of risk of bias assessment regarding the methodological quality of included studies—the risk of bias summary. Review the author's judgments about each risk of bias item for each included study.